Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

Libra aims at altered autophagy, neurotoxic protein production pathways shared across neurodegenerative disorders

By Sandi Wong, Assistant Editor
September 24, 2020 12:56 AM UTC

Axxam spinout Libra is targeting autophagy and toxic protein production pathways common to multiple neurodegenerative disorders, starting with ALS.

Libra Therapeutics Inc. emerged from stealth Wednesday with a $29 million series A co-led by Boehringer Ingelheim Venture Fund, Epidarex Capital and Santé Ventures and a trio of preclinical programs from Axxam S.p.A., which provides CRO services in addition to its internal drug discovery work. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Axxam S.p.A.